Low-Dose Anticholinergic Combination Therapy in Male Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms

LUTS: Lower Urinary Tract Symptoms

Volumn 4, Issue SUPPL. 1, 2012, Pages 102-109

  Park, Won Hee ^a   Gon Kim, Hyeong ^b  

^a Inha University School of Medicine   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

Anticholinergic drug; Benign prostatic hyperplasia; Low dose; Overactive bladder

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; PROPIVERINE; PROSTAGLANDIN SYNTHASE INHIBITOR; PURINERGIC RECEPTOR BLOCKING AGENT; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TOLTERODINE;

ADD ON THERAPY; BLADDER NECK STENOSIS; CLINICAL PRACTICE; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; GENERAL CONDITION IMPROVEMENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

EID: 84858629462     PISSN: 17575664     EISSN: 17575672     Source Type: Journal    
DOI: 10.1111/j.1757-5672.2011.00135.x     Document Type: Review

References (42)

1. Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urology 1994; 44: 153-5.
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
3. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979; 121: 640-2.
4. Chapple CR, Carter P, Christmas TJ et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-6.
5. Knutson T, Edlund C, Fall M, Dahlstrand C. BPH with coexisting overactive bladder dysfunction-an everyday urological dilemma. Neurourol Urodyn 2001; 20: 237-47.
6. Kakizaki H, Machino R, Koyanagi T. Clinical experience in lower urinary tract symptoms. BJU Int 2001; 88(Suppl 2): 23-6.
7. Seaman EK, Jacobs BZ, Blaivas JG, Kaplan SA. Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment. J Urol 1994; 152: 935-7.
8. Engström G, Henningsohn L, Walker-Engström ML, Leppert J. Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol 2006; 40: 485-94.
9. Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJ, Michel MC. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol 2010; 28: 3-8.
10. Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2001; 2: 1685-701.
11. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253-6.
12. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10.
13. Otsuka A, Shinbo H, Hasebe K, Matsumoto R, Ozono S. Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol 2008; 15: 1072-6.
14. Zagorodnyuk VP, Brookes SJ, Spencer NJ, Gregory S. Mechanotransduction and chemosensitivity of two major classes of bladder afferents with endings in the vicinity to the urothelium. J Physiol 2009; 587: 3523-38.
15. Jang J, Park EY, Seo SI, Hwang TK, Kim JC. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 2006; 98: 435-9.
16. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148: 565-78.
17. Jumadilova Z, Harris H, del Aguilla M, Wagner S, Boccuzzi S, Bavendam T. Agent selection for overactive bladder patients with and without documented comorbid benign prostatic hyperplasia. The 35th Annual Meeting of the International Continence Society; 28 Aug- 2 Sep 2005, Montreal, Canada. 2005.
18. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-20.
19. Saito H, Yamada T, Oshima H et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg 1999; 12: 525-36.
20. Lee KS, Choo MS, Kim DY et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174: 1334-8.
21. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296: 2319-28.
22. Roehrborn CG, Kaplan SA, Jones JS et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009; 55 472-9.
23. Chapple C, Herschorn S, Abrams P, Franklin Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur Urol 2009; 56: 534-43.
24. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009; 182: 2825-30.
25. Yamaguchi O, Kakizaki H, Homma Y et al., on behalf of the ASSIST Study Group. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms-ASSIST, randomized controlled study. Urology 2011; 78: 126-33.
26. Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systemic review and meta-analysis. BJU Int 2006; 99: 85-96.
27. Djavan B, Margreiter M, Dianat SS. An algorithm for medical management in male lower urinary tract symptoms. Curr Opin Urol 2011; 21: 5-12.
28. Lee KS, Lee HW, Han DH. Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn-Schmiedeberg's Arch Pharmacol 2008; 377: 491-501.
29. Kim JC, Lee KS, Choo MS, Park WH. Survey on the perception of Korean urologists toward the usage of anticholinergics in the treatment for male overactive bladder(OAB) patients. Korean J Urol 2010; 51(Suppl 1): 94.
30. Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 2004; 3: 46-53.
31. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 2003; 43: 1-5.
32. Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 2010; 29: 112-5.
33. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006; 25: 156-61.
34. Iijima K, De Wachter S, Wyndaele JJ. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007; 52: 842-7.
35. Yoshida M, Inadome A, Maeda Y et al. Non-neuronal cholinergic system in human bladder urothelium. Urology 2006; 67: 425-30.
36. Birder LA, Barrick SR, Roppolo JR et al. Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. Am J Physiol Renal Physiol 2003; 285: F423-9.
37. Fry CH, Sui GP, Kanai AJ, Wu C. The function of suburothelial myofibroblasts in the bladder. Neurourol Urodyn 2007; 26: 914-9.
38. Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006; 98: 503-7.
39. Seo KI, Hong SZ, Lee JB. The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean J Urol 2009; 50: 1078-82.
40. Lee KC, Cho IR. A study on the efficacy of combination therapy with alpha-blockers and anticholinergics in the lower urinary tract symptoms patients accompanied with overactive bladder symptoms. J Korean Continence Soc 2007; 11: 63-7.
41. Bae JH, Kim SO, Yoo ES, Moon KH, Kyung YS, Kim HJ. Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial. Korean J Urol 2011; 52: 274-8.
42. Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. LUTS 2011; 3: 29-35.